Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 610 clinical trials
LYT-100 in Healthy Volunteers and BCRL

Part 3 is a trial of up to 6-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast carcinoma patients with secondary lymphoedema

cancer surgery
lymphedema
reconstructive surgery
metastasis
breast cancer
  • 0 views
  • 19 Feb, 2024
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

cancer treatment
cutaneous t-cell lymphoma
dexamethasone
chronic lymphocytic leukemia
follicular lymphoma
  • 0 views
  • 19 Feb, 2024
  • 5 locations
Dupilumab Asthma Sleep Study

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

dupilumab
fractional exhaled nitric oxide
leukotriene receptor antagonist
corticosteroids
forced expiratory volume
  • 0 views
  • 19 Feb, 2024
  • 10 locations
HCV Reinfection After DAA Therapy in PWID in Belgium

The primary aim of this study is to calculate the incidence of HCV reinfection after successful DAA treatment among people who have recently injected drugs. The secondary aim is to identify factors associated with reinfection in this population. Individuals with active injecting drug abuse with a chronic HCV infection who …

hepatitis
  • 0 views
  • 19 Feb, 2024
Safety and Early Signs of Efficacy of IL12-L19L19.

The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD, as recommended dose (RD). The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.

estrogen
melanoma
b-cell lymphoma
squamous cell carcinoma of head and neck
solid tumors
  • 0 views
  • 19 Feb, 2024
Driving Pressure in Neurosurgery

Center of ventilation (COV) by EIT, as well as the lung ultrasonographyLUS), perioperative ventilatory parameters, arterial oxygenation index (PaO2/FiO2) , serum indicators and postoperative pulmonary complications are secondary outcome variables.

pulmonary complications
neurosurgery
oxygenation index
positive end expiratory pressure
  • 0 views
  • 19 Feb, 2024
Accuracy of Non-Invasive Blood Pressure Measurements at the Arm Calf and Finger

The intra-arterial measurement will be the reference measurement. As secondary objectives, the investigators will assess the ability of combined continuous (ClearSight) and intermittent (automatic cuff) non-invasive monitoring to detect stage 2 hypertension, and to detect changes in BP during a cardiovascular intervention (as clinically indicated but not imposed by the …

  • 0 views
  • 19 Feb, 2024
Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients

Loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients demonstrate diuretic resistance, requiring higher doses of the diuretics to achieve adequate diuresis. The cause of this diuretic resistance is hypothesized to be secondary to hypoalbuminemia which has led some providers to …

pleural effusion
diuretics
human serum albumin
edema
furosemide injection
  • 0 views
  • 19 Feb, 2024
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

refractory multiple myeloma
daratumumab
pomalidomide
proteasome inhibitor
autologous hematopoietic stem cell transplant
  • 0 views
  • 19 Feb, 2024
  • 8 locations
Early Prostate Cancer Recurrence With PSMA PET Positive Unilateral Pelvic Lesion(s)

If cancer recurs after surgical removal of the prostate, targeted PSMA PET (positron emission tomography) can detect metastases even at very low PSA (prostate-specific Antigen) values. This increasingly allows individualized specific therapy of patients with prostate cancer recurrence.

cancer recurrence
positron emission tomography
prostate specific antigen
local therapy
metastasis
  • 0 views
  • 19 Feb, 2024